Moberg Pharma AB Interim report July - September 2019
AGREEMENTS IN JAPAN AND THE REPUBLIC OF KOREAFIRST QUARTER (JUL-SEP 2019) · Net revenue SEK 47.8 million (15.6) * · R&D investments SEK 18.1 million (18.6) * · Operating profit (EBIT) SEK 41.8 million (5.0) * · Net profit after tax SEK 32.7 million (2.9) * · Diluted earnings per share SEK 1.76 (0.26) * · Cash and cash equivalents amounted to SEK 893.2 million (1,596.9) * All comparative figures refer to continuing operations The Annual General Meeting on October 30 has resolved to convert the company’s financial year from a fiscal year to the calendar year, July 1,